- About
- Programs
- Research
- Addressing Unmet Need Within the Animal and Veterinary Industries
- Antimicrobial Use Data in Food Animals
- Expanded Access Navigator
- Fellowship
- Food & Nutrition
- FDA Operational Evaluation
- FDA Patient Listening Sessions
- Improving Access to Publicly Available FDA Information
- Improving Understanding of the FDA and FDA-Regulated Products
- Substance Use Disorders
- COVID-19 Hub
- Regulatory Science Accelerator
- News and Events
- eRequest
Upcoming Events
Advancing Rare Disease Therapies Through an FDA Rare Disease Innovation Hub
Hybrid Public Meeting: In-Person and Virtual
Join us on October 7 to hear insights on the Final Rule on Requirements for Additional Traceability Records from both FDA leadership and other experts from across food industry sectors.
The Reagan-Udall Foundation for the FDA will be conducting a series of six closed-door virtual roundtable conversations with biosimilar developers to explore emerging areas of regulatory science and to create a space for active discussion and exploration between FDA and biosimilar developers.
Past Events
The Reagan-Udall Foundation for the FDA, in support of FDA’s ongoing focus on PTSD, convened “Advancing Treatments for Post-Traumatic Stress Disorder,” a public meeting with stakeholder comment.
The Reagan-Udall Foundation for the FDA, in collaboration with the Bill & Melinda Gates Foundation, will host a hybrid public workshop on "Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence."
-
The Food and Drug Administration (FDA) and the Reagan-Udall Foundation for the FDA convened the fifth Online Controlled Substances Summit.
Implementing the RAISE Action Framework
Webinar
July 16, 2024 | 2-3pm (eastern)
The Reagan-Udall Foundation for the FDA, in collaboration with the FDA, hosted a hybrid public workshop on "Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest."
The Reagan-Udall Foundation for the FDA, in collaboration with the Food and Drug Administration (FDA), hosted a public webinar as part of a series of webinars for FDA-issued guidance related to real-world evidence (RWE).
The Reagan-Udall Foundation for the FDA, in collaboration with FDA’s Rare Diseases Team within the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine; Office of New Drugs; Center for Drug Evaluation and Research and the National Institutes of Health’s Division of Rare Diseases Research Innovation within the National Center for Advancing Translational Sciences, is hosting a public workshop.
Each year, the Reagan-Udall Foundation for the FDA conducts an annual public meeting to discuss its activities in support of the U.S. Food and Drug Administration.
Qualifying Biomarkers to Support Rare Disease Regulatory Pathways
-
Advancing Psychedelic Clinical Study DesignVirtual Public Meeting
Day 1: January 31, 2024 | 10am-2pm (eastern)